Prostatic Artery Embolization for Treatment of Benign Prostatic Hyperplasia in Patients with Prostates > 90 g: A Prospective Single-Center Study
Carregando...
Citações na Scopus
125
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Citação
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, v.26, n.1, p.87-93, 2015
Resumo
Purpose: To describe the safety and efficacy of prostatic artery embolization (PAE) with spherical microparticles to treat lower urinary tract symptoms associated with benign prostatic hyperplasia in patients with prostate volume > 90 g. Materials and Methods: This prospective, single-center, single-arm study was conducted in 35 patients with prostate volumes ranging from 90-252 g. Mean patient age was 64.8 years (range, 53-77 y). Magnetic resonance imaging, uroflowmetry, and the International Prostate Symptom Score (IPSS) were used to assess clinical and functional outcomes. Results: Mean prostate size decreased significantly from 135.1 g before PAE to 91.9 g at 3 months of follow-up (P < .0001). Mean IPSS and quality-of-life index improved from 18.3 to 2.7 and 4.8 to 0.9 (P < .0001 for both), respectively. A significant negative conelation was observed between prostate-specific antigen at 24 hours after PAE and IPSS 3 months after PAE (P = .0057). Conclusions: PAE is a safe and effective treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia in patients with prostate volume > 90 g. Excessively elevated prostate-specific antigen within 24 hours of PAE is associated with; lower symptom burden in short-term follow-up.
Palavras-chave
Referências
- Angle JF, 2010, J VASC INTERV RADIOL, V21, P1479, DOI 10.1016/j.jvir.2010.06.014
- Antunes AA, 2013, CARDIOVASC INTER RAD, V36, P978, DOI 10.1007/s00270-013-0611-5
- Bagla S, 2014, J VASC INTERV RADIOL, V25, P47, DOI 10.1016/j.jvir.2013.09.010
- Bihim T, 2012, J VASC INTERV RADIOL, V23, P1403
- Bilhim T, 2013, CARDIOVASC INTER RAD, V36, P403, DOI 10.1007/s00270-012-0528-4
- Briant PE, 2014, PROG UROL, V24, P379
- Carnevale FC, 2013, J VASC INTERV RADIOL, V24, P535, DOI 10.1016/j.jvir.2012.12.019
- Carnevale PC, 2010, CARDIOVASC INTERVENT, V33, P355
- Emberton M, 2003, UROLOGY, V61, P267, DOI 10.1016/S0090-4295(02)02371-3
- Gao YA, 2014, RADIOLOGY, V270, P920, DOI 10.1148/radiol.13122803
- Geavlete B, 2013, BJU INT, V111, P793, DOI 10.1111/j.1464-410X.2012.11730.x
- Golzarian J, 2014, J VASC INTERV RADIOL, V25, P665, DOI 10.1016/j.jvir.2013.11.003
- Homma Y, 2011, INT J UROL, V18, P741, DOI 10.1111/j.1442-2042.2011.02860.x
- Juliao AA, 2012, CURR OPIN UROL, V22, P34, DOI 10.1097/MOU.0b013e32834d8e87
- Kuntz RM, 2008, EUR UROL, V53, P160, DOI 10.1016/j.eururo.2007.08.036
- Kwon Joon Seok, 2011, Korean J Urol, V52, P269, DOI 10.4111/kju.2011.52.4.269
- McVary KT, 2011, J UROLOGY, V185, P1793, DOI 10.1016/j.juro.2011.01.074
- Moslemi MK, 2010, UROL J, V7, P51
- Naspro R, 2006, EUR UROL, V50, P563, DOI 10.1016/j.eururo.2006.04.003
- Nikolic B, 2000, RADIOLOGY, V214, P121
- Oelke M, 2013, EUR UROL, V64, P118, DOI 10.1016/j.eururo.2013.03.004
- Pisco JM, 2013, EUR RADIOL, V23, P2561, DOI 10.1007/s00330-012-2714-9
- Rassweiler J, 2006, EUR UROL, V50, P969, DOI 10.1016/j.eururo.2005.12.042
- Srougi M, 2011, HIPERPLASIA PROSTATI, P111